Avidity Biosciences Inc. (RNA) News
Filter RNA News Items
RNA News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
RNA News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest RNA News From Around the Web
Below are the latest news stories about AVIDITY BIOSCIENCES INC that investors may wish to consider to help them evaluate RNA as an investment opportunity.
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that on January 6, 2025, the Human Capital Management Committee of Avidity's Board of Directors granted a non-qualified stock option award to purchase an aggregate of 80,000 shares of its common stock and 40,000 restricted stock units ("RSUs") to Charles Calderaro III, under the Avidity Biosciences, Inc. 2 |
Avidity Biosciences Plans to Submit First Biologics License Application This YearAvidity Biosciences (RNA) said Wednesday it plans to file a biologics license application for delpac |
Avidity Biosciences Plans First BLA Submission and Accelerates Commercialization Preparations for Three Rare Muscle Disease Programs in 2025Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced its progress and planning for a transformational year in 2025. These major anticipated milestones include executing on three potentially registrational programs, filing a Biologics License Application (BLA) for delpacibart zotadirsen (del-zota) for people living with Duchenne muscular dystrophy mutations a |
Why Is Avidity Biosciences, Inc. (RNA) Among the Best Multibagger Stocks to Buy Right Now?We recently compiled a list of the 12 Best Multibagger Stocks to Buy Right Now. In this article, we are going to take a look at where Avidity Biosciences, Inc. (NASDAQ:RNA) stands against the other multibagger stocks. The US equities continued their upward movement in 2024 and fueled the S&P 500 to record highs. Much of […] |
Avidity Biosciences to Participate in Upcoming Investor ConferenceAvidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that Avidity management will be participating in the following upcoming conference: |
Biotech Stock Roundup: NVAX Q3 Results, SNDX Down on AML Data, RNA Surges on Study DataNVAX and RNA are in the spotlight following Q3 results and study data, respectively. |
RNA Stock Hits Record High on Entering the Cardiac Disease SpaceAvidity Biosciences expands its pipeline to include two new drugs targeting rare genetic cardiomyopathies. |
Avidity Bio Has Surged 416% This Year — And That's Before Today's 'Game-Changing' NewsShares of Avidity Biosciences surged to a record high Wednesday after the company showed its hand in the cardiovascular space. |
Avidity Biosciences Announces New Precision Cardiology Development Candidates to Treat Rare Genetic Cardiomyopathies and Provides First Look at Next-Generation Technology InnovationsAvidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced it has expanded beyond rare skeletal muscle disorders and is opening up a new therapeutic field, precision cardiology, to address the root cause of genetic diseases of the heart. Avidity is advancing its first two new wholly-owned precision cardiology development candidates targeting rare genetic cardiomyo |
Avidity Biosciences Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues LagAvidity Biosciences ( NASDAQ:RNA ) Third Quarter 2024 Results Key Financial Results Revenue: US$2.34m (down 17% from 3Q... |